A vendor can post a chromatogram that looks clean, sharp, and highly technical while still leaving critical questions unanswered. Knowing how to read chromatography reports helps separate meaningful batch evidence from a document that merely borrows the appearance of quality control. For research-use-only peptides, a chromatogram should be evaluated alongside the full Certificate of Analysis, the stated method, and proof that the tested material matches the product being offered.
What a chromatography report can actually tell you
Chromatography separates components in a sample so they can be detected individually. For peptide products, vendors commonly use high-performance liquid chromatography, or HPLC. The instrument passes a prepared sample through a column, and compounds move through that column at different rates. The detector records signals over time, producing the familiar chart of peaks.
A chromatography report can support a claim about chromatographic purity. It may show whether one component dominates the sample and whether visible impurities are present under that specific method. It does not, by itself, prove every quality claim a vendor may make.
A clean HPLC trace is not automatic confirmation of peptide sequence, vial fill quantity, sterility, endotoxin status, or the absence of all contaminants. Those questions require different methods and, in many cases, different tests. A supplier that treats one chromatogram as proof of everything is asking buyers to make an unsupported leap.
How to read chromatography reports: start with the report context
Before interpreting the peaks, confirm that the report can be tied to a real, current product batch. Look for a product name, lot or batch number, test date, laboratory name, sample identifier, and a clear result tied to the submitted sample. The lot number on the chromatography report should match the lot number on the COA and, where practical, the lot being sold.
Dates matter. A report from years ago may demonstrate that a supplier tested something at one point. It does not establish current batch control. Likewise, a generic file labeled with only a compound name is weak evidence because there is no reliable way to connect it to the vial a researcher receives.
Independent laboratory documentation carries more weight than an internally generated chart. That does not mean an internal quality-control result is worthless, but the conflict is obvious: the seller controls both the material and the reported outcome. Independent testing creates a more credible separation between marketing and verification.
Read the axes before judging the peaks
Most chromatograms use time on the horizontal axis and detector response on the vertical axis. The horizontal axis is generally retention time, often expressed in minutes. Retention time is when a compound reaches the detector under the stated method.
The vertical axis may be absorbance, milli-absorbance units, intensity, or another detector response. A taller peak can indicate more detector response, but peak height alone is not the proper measure of purity. Width, integration settings, detector behavior, and sample concentration all affect the appearance of a peak.
Pay attention to the detector listed on the report. Many peptide reports use UV detection at a stated wavelength, such as 214 nm or 220 nm, because peptide bonds absorb in this range. UV-HPLC is useful, but it is not universally specific. Different substances can produce signals at the selected wavelength, and some impurities may be poorly detected or missed under a given set of conditions.
That limitation is why identity confirmation should not rest on retention time alone. A properly supported identity claim often includes mass spectrometry, such as LC-MS, compared with the expected molecular mass. Chromatography tells you how the material separated. Mass data helps establish what the main component is.
Understand the main peak and the purity percentage
The largest peak is usually presented as the target compound. Its retention time should be listed in a peak table, along with peak area and area percentage. In a typical area-normalization calculation, the main peak area is divided by the total integrated peak area, then reported as a percentage.
For example, a reported 99% purity often means the primary integrated peak accounts for 99% of the detected chromatographic area under that method. It does not necessarily mean 99% of the vial's mass is active peptide, and it does not mean 1% is the only possible impurity burden in every chemical sense.
The distinction matters. Area percentage depends on the detector, wavelength, column, mobile phase, gradient, integration rules, and how different compounds respond to the detector. A 99% HPLC result can be meaningful evidence of high chromatographic purity when the report is complete and method is appropriate. It should not be converted into a blanket guarantee about identity, quantity, or biological safety.
Small secondary peaks deserve context, not automatic panic. Peptides can show related substances, deletion sequences, oxidation products, residual synthesis materials, or degradation products. The relevant question is whether the peaks are disclosed, consistently measured, and within a defined specification. A report showing unexplained peaks without a stated acceptance criterion gives less decision-ready information than a report that identifies the method and the pass/fail standard.
Look for the method, not just the chart
A credible chromatography package identifies enough of the method for a reviewer to understand what was tested. At minimum, look for the technique, column type, mobile phases, gradient or run conditions, flow rate, detector and wavelength, injection amount or sample concentration, and integration approach.
Not every public-facing COA needs to publish a laboratory's full proprietary method. Still, there must be enough detail to establish that a defined method exists. A screenshot of a single peak with no axes, no method, no sample ID, and no peak table is not a useful analytical record.
Method suitability depends on the compound. A method that cleanly resolves one short peptide may not adequately resolve related impurities in a longer or more complex sequence. The practical standard is not that every buyer becomes a chromatographer. It is that vendors provide documentation detailed enough for qualified reviewers to assess whether the claimed result has a defensible basis.
Confirm what chromatography cannot confirm
For peptide supplier evaluation, chromatography is one piece of a testing package. It should be paired with evidence that addresses separate quality attributes:
Identity testing, commonly mass spectrometry, supports that the primary compound matches the expected molecular mass.
Net content or conformity testing addresses whether the stated amount in the vial is supported, rather than assuming purity equals fill quantity.
Sterility testing evaluates microbial growth under specified conditions for products presented as sterile.
Endotoxin testing evaluates bacterial endotoxin burden, which chromatography does not measure.
Heavy metals testing addresses elemental contamination that an HPLC purity trace may not reveal.
These categories are not interchangeable. A product can show a high reported HPLC purity and still lack current evidence for net content, endotoxin, or sterility. Researchers should match the documentation to the claim being made instead of accepting a single attractive number as a substitute for a complete quality picture.
Red flags that should stop the evaluation
Some problems are obvious once you know where to look. A chromatogram without a laboratory name, analyst authorization, date, or batch number cannot be reliably traced. A report that shows only “purity: 99%” without raw trace data or a peak table offers little basis for independent review.
Be cautious when the report is visibly edited, uses inconsistent compound names, contains cropped axes, or displays a lot number that does not appear anywhere else in the vendor's documentation. Also question claims of exceptional purity when the chromatogram has broad, overloaded, poorly resolved, or unintegrated peaks. A large main peak can hide poor separation from nearby impurities.
The absence of a reference standard or identity-confirming method is another limitation. Retention time matching can support a result, but it is not the same as proving identity. If a vendor will not explain what method was used or cannot provide batch-specific documentation, the appropriate response is not to fill in the gaps with trust.
Use a decision standard, not a visual impression
The most reliable reading process is comparative. First, verify the batch connection. Then assess whether the chromatogram includes a complete trace, peak table, method details, and a clearly stated purity result. Finally, check whether identity and other relevant quality attributes have separate supporting tests.
This approach also prevents a common mistake: choosing a supplier based on the highest advertised purity figure alone. A 99.5% result with no batch traceability or identity evidence may be less useful than a slightly lower reported result supported by an independent lab, current lot documentation, LC-MS identity data, and appropriate conformity testing.
At RUO Codes, independent testing documentation is the baseline because documentation is the point where quality claims become reviewable. Discounts and polished product pages can be useful purchasing information, but they do not compensate for missing evidence.
A chromatography report should leave you with more than confidence in a clean-looking peak. It should give you a traceable, method-specific reason to believe that the tested batch contains a predominant component consistent with the claim - and a clear understanding of which questions still require separate proof.